Showing results (541-550 of 579) with videos related to
Sort By:
Pageof 58
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.British Journal of Haematology|September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemiaWei-Ying Jen, Guilin Tang, Eitan Kugler, et al.Cancer|April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.Cell|November 5, 2025
Disparate leukemia mutations converge on nuclear phase-separated condensatesGandhar K Datar, Elmira Khabusheva, Archish Anand, et al.Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.American Journal of Hematology|March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaKoji Sasaki, Hagop Kantarjian, William Wierda, et al.Cancer|April 1, 2021
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemiaCaitlin R Rausch, Courtney D DiNardo, Abhishek Maiti, et al.Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.Pageof 58